Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of tislelizumab combined with radiotherapy for BCG-failed non-muscle-invasive bladder cancer
ChiCTR2000035275Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in bladder cancer and non-muscle-invasive bladder cancer (NMIBC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: recurrence-free survival. Started Sep 2020; status: completed.
02
Drugs
tislelizumab
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR2000035275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035275.